Skip to main content
. Author manuscript; available in PMC: 2018 Feb 2.
Published in final edited form as: Kidney Int. 2017 Jul 29;93(2):375–389. doi: 10.1016/j.kint.2017.05.014

Figure 8. miR-21-5p effect on fibrosis and hypertrophy.

Figure 8

(a) Anti-miR-21-5p treatment of 5/6 nephrectomy (5/6Nx) rats had no effect on the abundance left ventricular perivascular fibrosis; however, it significantly reduced the average cross-sectional left ventricular cardiomyocyte area in wheat germ agglutinin-treated left ventricular sections (b). N = 5-6 per group; *P < 0.05 versus sham controls and #P < 0.05 versus anti-scr 5/6 Nx control; 2-way analysis of variance. (c) The ability of miR-21-5p inhibition to prevent hypertrophic growth was tested in H9C2 cells treated with insulin-like growth factor (IGF-1) (50 ng/ml) for 24 hours. Transfection of cells with anti-miR-21 prevented the IGF-1 -induced increase in H9C2 area (vs. anti-scr transfected cells). N = 3 per group; †P < 0.05 versus IGF-1 control (saline), and *P < 0.05 versus miR-21 control (anti-scr + IGF); 2-way analysis of variance. Avg., average; LV, left ventricle; scr, scrambled. Bar = 100 μm. To optimize viewing of this image, please see the online version of this article at www.kidney-international.org.